Bristol-Meyers Squibb Acquires Cardioxyl Pharmaceuticals for $2,075,000,000
Feed Type
Link http://www.venturedeal.com/Search/SearchResultTransactionDetail.aspx?TransactionId=50a03547-6f0e-4609-bb65-0f58781fdcaf
Date 11/2/2015
Company Name Cardioxyl Pharmaceuticals
Mailing Address 1450 Raleigh Road Chapel Hill, NC 27517 USA
Company Description Cardioxyl Pharmaceuticals’ mission is the discovery and development of newclasses of safe and effective therapeutic agents for the treatment ofcardiovascular disease. Cardioxyl’s initial program is a novel medication forthe treatment of acute decompensated heart failure.
M&A Terms The transaction includes upfront and near-term milestone payments of up to $300 million and potential additional consideration of up to $1.775 billion upon the achievement of certain development, regulatory and sales milestones.